

Docket No.: TDT-ADV-056(TJU0001-107)
PATENT

Appl. Number: 10/621,684
Filed: 07/17/03

In the Claims:

1-22. (Canceled)

23. (New) A pharmaceutical composition comprising:

- a) a ST receptor binding ligand; and,
- b) a radiostable active agent.

24. (New) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide.

25. (New) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides.

26. (New) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

27. (New) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

28. (New) The pharmaceutical composition of claim 23 wherein said an active agent is a therapeutic agent.

29. (New) The pharmaceutical composition of claim 23 wherein said an active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine,

Docket No.: TDT-ADV-056(TJU0001-107)
PATENT

Appl. Number: 10/621,684
Filed: 07/17/03

mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

30. (New) The pharmaceutical composition of claim 23 wherein said an active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, and 1,4-benzoquinone derivatives.

31. (New) The pharmaceutical composition of claim 23 wherein said an active agent is 5-fluorouracil.

32. (New) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides, and the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

33. (New) The pharmaceutical composition of claim 32 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

Docket No.: TDT-ADV-056(TJU0001-107)
PATENT

Appl. Number: 10/621,684
Filed: 07/17/03

34. (New) The pharmaceutical composition of claim 32 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

35. (New) The pharmaceutical composition of claim 32 wherein said an active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, and 1,4-benzoquinone derivatives.

36. (New) The pharmaceutical composition of claim 32 wherein said an active agent is 5-fluorouracil.

37. (New) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54 and the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, and 1,4-benzoquinone derivatives.

38. (New) The pharmaceutical composition of claim 37 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

39. (New) The pharmaceutical composition of claim 37 wherein said an active agent is 5-fluorouracil.

40. (New) The pharmaceutical composition of claim 39 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

Docket No.: TDT-ADV-056(TJU0001-107)
PATENT

Appl. Number: 10/621,684
Filed: 07/17/03

41. (New) The pharmaceutical composition of claim 23 wherein said pharmaceutical composition is an injectable pharmaceutical composition.
42. (New) The pharmaceutical composition of claim 23 wherein said pharmaceutical composition is a liposome comprising a vesicle matrix wherein the ST receptor binding ligand is in the vesicle matrix and the active agent is inside the liposome.
43. (New) The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides, and the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cisplatin, vindesine, mitomycin, bleomycin, puromycin, macromycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.
44. (New) The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2 said the active agent is 5-fluorouracil.